Aimmune Therapeutics

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.

Company Growth (employees)
Type
Public
HQ
Brisbane, US
Founded
2011
Size (employees)
102 (est)+26%
Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US

Aimmune Therapeutics Office Locations

Aimmune Therapeutics has offices in Brisbane and Greater London
Brisbane, US (HQ)
200 8000 Marina Blvd
Greater London, GB
344-354 Grays Inn Rd

Aimmune Therapeutics Data and Metrics

Aimmune Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(25.9 m)

EBIT (Q1, 2017)

(26.3 m)

Market capitalization (18-Aug-2017)

957.9 m

Cash (31-Mar-2017)

78.7 m
Aimmune Therapeutics's current market capitalization is $957.9 m.
USDFY, 2015FY, 2016

R&D expense

19.8 m54.6 b

General and administrative expense

16.2 m26.9 b

Operating expense total

36 m81.5 b

EBIT

(36 m)(81.5 b)

Interest expense

(36 k)

Interest income

217 k

Pre tax profit

(35.8 m)(80.8 b)

Net Income

(35.8 m)(80.8 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

3.1 m3.9 m10 m11.8 m15.9 m17.4 m

General and administrative expense

4.2 m5.2 m5.7 m6.5 m6.4 m8.9 m

Operating expense total

7.4 m9 m15.7 m18.3 m22.2 m26.3 m

EBIT

(7.4 m)(9 m)(15.7 m)(18.3 m)(22.2 m)(26.3 m)

Interest expense

(24 k)(25 k)

Interest income

1 k33 k215 k231 k

Net Income

(9 m)(15.5 m)(18.1 m)(22.1 m)(25.9 m)
USDFY, 2015FY, 2016

Cash

76.7 m124 m

Inventories

5.6 m2.7 m

Current Assets

197.5 m251.7 m

PP&E

2.7 m10.4 m

Total Assets

212.4 m298.8 m

Accounts Payable

1.9 m1.4 m

Current Liabilities

5.1 m11.5 m

Total Liabilities

12.8 m

Additional Paid-in Capital

259.7 m420.2 m

Retained Earnings

(53.3 m)(134.2 m)

Total Equity

206.3 m286 m

Financial Leverage

1 x1 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

58.5 m112.7 m65 m74.4 m76.9 m78.7 m

Current Assets

60.6 m217.8 m185.2 m172.8 m152.6 m248.9 m

PP&E

1.3 m1.8 m3.7 m7 m9 m11.1 m

Total Assets

62.1 m222.8 m199.9 m185.7 m173.7 m276.3 m

Accounts Payable

309 k1 m1.8 m1.3 m1.5 m1.7 m

Current Liabilities

3.3 m3.1 m5.3 m5.8 m11.8 m10.2 m

Additional Paid-in Capital

2.5 m256.2 m262.2 m265.5 m269.6 m424.9 m

Retained Earnings

(28.3 m)(37.3 m)(68.9 m)(87 m)(109.1 m)(160 m)

Total Equity

58 m218.9 m193.4 m178.5 m160.5 m264.7 m

Financial Leverage

1.1 x1 x1 x1 x1.1 x1 x
USDFY, 2015FY, 2016

Net Income

(35.8 m)(80.8 m)

Depreciation and Amortization

115 k534 k

Inventories

4 m

Accounts Payable

1.1 m(994 k)

Cash From Operating Activities

(35.7 m)(56.6 m)

Purchases of PP&E

(1.7 m)(7.7 m)

Cash From Investing Activities

(125.2 m)(43.9 m)

Cash From Financing Activities

235.3 m147.8 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9 m)(15.5 m)(18.1 m)(22.1 m)(25.9 m)

Accounts Payable

309 k1 m1.8 m1.3 m1.5 m1.7 m
Y, 2017

Financial Leverage

1 x

Aimmune Therapeutics Operating Metrics

FY, 2016

Patents Issued

2

Aimmune Therapeutics Market Value History

Traffic Overview of Aimmune Therapeutics

Aimmune Therapeutics Online and Social Media Presence

Aimmune Therapeutics Company Life and Culture

You may also be interested in